Tom 16, Nr 3 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-06-30
Wyświetlenia strony
331
Wyświetlenia/pobrania artykułu
522
Clinician’s guide for dapagliflozin use in heart failure with reduced ejection fraction
DOI: 10.5603/FC.2021.0022
Folia Cardiologica 2021;16(3):191-197.
Streszczenie
Dapagliflozin belongs to a new class of drugs used for the treatment of heart failure — sodium-glucose cotransporter type 2 inhibitors (SGLT2i). Based on the DAPA-HF study results, dapagliflozin has become the first SGLT2i approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction. The present review summarizes the most important clinical issues related to the treatment with this drug.
Słowa kluczowe: heart failure with reduced ejection fractionSGLT2 inhibitorsdapagliflozin
